Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

Lineage Cell Therapeutics (LCTX) Leases (2016 - 2025)

Historic Leases for Lineage Cell Therapeutics (LCTX) over the last 10 years, with Q3 2025 value amounting to $2.3 million.

  • Lineage Cell Therapeutics' Leases fell 215.92% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 215.92%. This contributed to the annual value of $2.1 million for FY2024, which is 1498.81% down from last year.
  • Lineage Cell Therapeutics' Leases amounted to $2.3 million in Q3 2025, which was down 215.92% from $1.8 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' Leases' 5-year high stood at $3.5 million during Q4 2022, with a 5-year trough of $28000.0 in Q1 2022.
  • Its 5-year average for Leases is $2.4 million, with a median of $2.5 million in 2022.
  • Its Leases has fluctuated over the past 5 years, first plummeted by 9894.26% in 2022, then soared by 1138214.29% in 2023.
  • Quarter analysis of 5 years shows Lineage Cell Therapeutics' Leases stood at $2.4 million in 2021, then skyrocketed by 48.27% to $3.5 million in 2022, then fell by 28.29% to $2.5 million in 2023, then fell by 14.99% to $2.1 million in 2024, then increased by 7.79% to $2.3 million in 2025.
  • Its Leases was $2.3 million in Q3 2025, compared to $1.8 million in Q2 2025 and $1.9 million in Q1 2025.